Nuvectis Pharma, Inc. (NVCT)
Nasdaq: NVCT · Pharmaceutical Preparations · Fort Lee, NJ · filing with the SEC since 2021
Who owns Nuvectis Pharma, Inc.
As filed with the SECHolders of 5% or more
1
Soleus Capital Management, L.P. holds 5.1% of Common Stock, par value $0.00001 per share, as its SCHEDULE 13G filed Aug 6, 2026 says.
Directors and officers
8
report now, of 9 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Soleus Capital Management, L.P.
SCHEDULE 13G · filed Aug 6, 2026 · Common Stock, par value $0.00001 per share
What NVCT reports owning in othersstakes of 5% or more, and other ties
Nuvectis Pharma, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
4purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$400,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 10 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% owner | 0 | $0 | 0 | 4 | $1.9M |
| Bentsur Ron | Chairman & CEO | 0 | $0 | 0 | 2 | $300,000 |
| Kaplan Matthew L. | director | 0 | $0 | 0 | 1 | $100,000 |
| Sanchez Juan | director | 0 | $0 | 0 | 1 | $100,000 |